Most patients have unrealistic survival expectations, which may compromise their ability to make informed treatment decisions.
Patients with a relatively low tumor risk and good general health status appear to experience the best survival.
In a meta-analysis, men with benign prostatic hyperplasia had a 2.9 times and 1.7 times increased incidence of prostate cancer and bladder cancer, respectively.
High rates of screening for individuals with limited long-term life expectancy for all tools.
Multiple studies suggest they might.
Researchers found an adjusted 68% decreased risk of prostate cancer in men with IBD who used aminosalicylate.
Prostate cancer patients taking proton pump inhibitors also had pathologically higher stage disease.
The higher the baseline PSA levels, the greater the risk of being diagnosed with any or significant prostate cancer.
Minimally invasive surgery is associated with a lower incidence of bladder neck contracture.
Study documents superior recurrence- and metastasis-free survival compared with cT1b tumors.
A biologic effective dose less than 170 Gy2 is associated with a 2-fold increase risk dying from prostate cancer versus higher doses.
The chances of erectile function recovery improved when patients received radiation treatment more than 16 months after surgery.
In a study, use of the medication was associated with a significant 61% decreased risk.
In fact, some data suggest treatment may reduce prostate cancer incidence and aggressiveness.
The increased risk occurs more than 10 years after treatment and most pronounced in men who undergo brachytherapy.
In a study of African-American radical prostatectomy patients, low income predicted a higher risk of advanced stage or aggressive tumors.
Potency is preserved in 50.4% and 60.8% of patients at 10 years after seed implantation, according to MSSFI and SHIM scores, respectively.
New findings show metabolic changes suggesting that a carbohydrate-restricted diet may improve insulin sensitivity.
New study shows that heavier comorbidity burdens increase the risk of Gleason 7 or higher tumors being found at biopsy.
Mechanism may explain prostate cancer treatment resistance among African-American men.
The PLCO trial's conclusion that routine PSA testing does not affect prostate cancer mortality risk could be wrong.
Findings support the use of a 5 grade-group system that more accurately reflects patient risk of adverse outcomes.
The odds of PSA screening were higher among blacks than non-Hispanic whites.
PSA level declined by an average of 0.68 ng/mL in the treatment group.
An early, integrated approach led to less deterioration of erectile function after surgery.
Researchers also suggests that statins may help counteract harmful effect of fatty foods.
Testosterone levels of 20 ng/dL or less were achieved and maintained by more than 90% of men with advanced prostate cancer.
Improved odds seen for patients with colon, prostate, or breast tumors, but research isn't definitive.
Molecular pathways identified that may serve as potential biomarkers in prostate cancer treated with stereotactic body radiation therapy (SBRT).
Researchers found that men who exercised the most had the best outcomes.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)